Dyadic International, Inc., a global biotechnology company, has filed a prospectus supplement with the SEC for a proposed public offering of common stock. Craig-Hallum Capital Group LLC is serving as the sole managing underwriter for the offering. The company plans to use the net proceeds for working capital and general corporate purposes, which include product development and sales and marketing efforts. The offering is contingent on market conditions, and the final terms will be detailed in a forthcoming final prospectus supplement. Interested parties can access the prospectus through the SEC's website or by contacting Craig-Hallum Capital Group LLC.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.